Heart Failure Reviews最新文献

Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated. 心力衰竭和慢性阻塞性肺病。这是一个不可低估的组合。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-10-07 DOI: 10.1007/s10741-025-10566-3

Damiano Magrì, Emiliano Fiori, Piergiuseppe Agostoni, Michele Correale, Massimo Piepoli, Savina Nodari, Matteo Beltrami, Stefania Paolillo, Pasquale Perrone Filardi, Alberto Palazzuoli

{"title":"Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated.","authors":"Damiano Magrì, Emiliano Fiori, Piergiuseppe Agostoni, Michele Correale, Massimo Piepoli, Savina Nodari, Matteo Beltrami, Stefania Paolillo, Pasquale Perrone Filardi, Alberto Palazzuoli","doi":"10.1007/s10741-025-10566-3","DOIUrl":"https://doi.org/10.1007/s10741-025-10566-3","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) and heart failure (HF) frequently coexist and interact through complex and bidirectional hemodynamic mechanisms that amplify symptoms' burden and complicate clinical management. The present review explores the impact of COPD across the HF spectrum, particularly in HF with preserved ejection fraction (HFpEF), where comorbidities, such as COPD, exert a dominant role in disease expression. COPD-induced hyperinflation reduces cardiac preload and increases right ventricular afterload, while HF-related congestion impairs pulmonary function and gas exchange, illustrating a tight cardiorespiratory coupling. Diagnostic challenges stem from overlapping symptoms and the limited specificity of biomarkers, such as natriuretic peptides, especially in HFpEF. Cardiopulmonary exercise testing (CPET) emerges as a valuable tool for distinguishing between cardiac and pulmonary limitations and guiding individualized treatment strategies. From a therapeutic standpoint, β1-selective blockers are not only safe in COPD patients but are pivotal in those with HF with reduced ejection fraction (HFrEF), where they have been demonstrated to improve survival and reduce both HF and COPD exacerbations. Concerns regarding bronchodilator safety in HF remain largely theoretical, with current evidence supporting their continued use when clinically indicated. Ultimately, optimal care for patients with coexisting COPD and HF requires a phenotype-specific approach, incorporating insights from pathophysiology, diagnostic innovation, and evidence-based pharmacotherapy to improve outcomes in this challenging patient population.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating heart failure: a plain-language summary to empower people with heart failure. 导航心力衰竭：一个简单的语言总结，以授权与心力衰竭的人。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-10-01 DOI: 10.1007/s10741-025-10567-2

Jillianne Code, Andrew J Sauer, Robert J Mentz, Rhonda E Monroe

{"title":"Navigating heart failure: a plain-language summary to empower people with heart failure.","authors":"Jillianne Code, Andrew J Sauer, Robert J Mentz, Rhonda E Monroe","doi":"10.1007/s10741-025-10567-2","DOIUrl":"https://doi.org/10.1007/s10741-025-10567-2","url":null,"abstract":"Heart failure is a chronic condition that can result from multiple causes and occurs when the heart cannot pump enough blood to meet the body's needs. Heart failure is often classified by ejection fraction (or 'heart squeeze'), into three categories: preserved, mildly reduced, or reduced ejection fraction. Diagnosing heart failure can be challenging. Common symptoms such as fatigue and shortness of breath may overlap with other conditions and can be missed by healthcare professionals. While heart failure can lead to serious health problems, it is a manageable condition through medical interventions that target the underlying causes along with nutrition and lifestyle approaches. Comprehensive care should also include addressing the impact of heart failure on mental health. Effective therapies can help patients with heart failure feel better, function better, stay out of hospital, and live longer. Working towards acceptance of a heart failure diagnosis and embracing self-care are key positive steps for improving quality of life. Effective healthcare professional-patient relationships are critical. Open communication allows healthcare providers, including specialist nurses and clinicians, along with primary healthcare professionals, to fully understand a patient's condition and recommend suitable treatment approaches. It may also motivate patients to adhere to therapies and adopt lifestyle changes. This review aims to empower patients with heart failure by providing clear information on diagnosis and treatment, as well as providing real-life patient perspectives that can support effective communication with healthcare providers.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phenotype-guided approach for device-based therapies in heart failure. 以表型为导向的心衰器械治疗方法。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-30 DOI: 10.1007/s10741-025-10565-4

Phuuwadith Wattanachayakul, Veraprapas Kittipibul, William T Abraham, Rebecca T Hahn, Sean P Pinney, Akshay S Desai, Daniel Burkhoff, Marat Fudim

引用次数: 0

Heart failure and left ventricular ejection fraction: a necessary but imperfect partnership. 心力衰竭和左心室射血分数：必要但不完美的伙伴关系。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-27 DOI: 10.1007/s10741-025-10563-6

Alberto Palazzuoli, Gaetano Ruocco, Andrew P Ambrosy

{"title":"Heart failure and left ventricular ejection fraction: a necessary but imperfect partnership.","authors":"Alberto Palazzuoli, Gaetano Ruocco, Andrew P Ambrosy","doi":"10.1007/s10741-025-10563-6","DOIUrl":"https://doi.org/10.1007/s10741-025-10563-6","url":null,"abstract":"The left ventricular ejection fraction (LVEF) is the most commonly used index to assess left ventricular systolic function and guide management in patients with heart failure (HF). This is largely due to the widespread availability of echocardiography, its practicality, rapid scan time, ease of measuring left ventricular (LV) volumes, and its extensive application in both clinical practice and research. Accordingly, a recent joint clinical consensus statement from the Heart Failure Association (HFA) and the Heart Failure Society of America (HFSA) recommends that LVEF be evaluated longitudinally to assess disease trajectory, natural history, and response to treatment in patients with heart failure (6). However, there is little, if any, evidence that serial LVEF assessment improves risk stratification or guides management in HF. Notably, LVEF may not accurately reflect overall cardiac function. While it is commonly used as a measure of systolic function, LVEF does not fully capture the status of the heart. Other parameters-such as diastolic function, ventricular size, valvular function, and right ventricular function-also play important roles in determining patient risk. This paper proposes an alternative strategy, shifting from serial LVEF evaluation to a more comprehensive approach that includes assessment of congestion, right ventricular function, and structural myocardial damage to provide more robust diagnostic and prognostic information.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diabetic cardiomyopathy: Mechanistic insights on molecular pathways and emerging therapeutic approaches. 糖尿病性心肌病：分子途径和新兴治疗方法的机制见解。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-27 DOI: 10.1007/s10741-025-10562-7

Rupinder Kaur, Shubhdeep Singh, Pragati Sood, Shareen Singh, Souvik Banerjee, Thakur Gurjeet Singh

{"title":"Diabetic cardiomyopathy: Mechanistic insights on molecular pathways and emerging therapeutic approaches.","authors":"Rupinder Kaur, Shubhdeep Singh, Pragati Sood, Shareen Singh, Souvik Banerjee, Thakur Gurjeet Singh","doi":"10.1007/s10741-025-10562-7","DOIUrl":"https://doi.org/10.1007/s10741-025-10562-7","url":null,"abstract":"Diabetes and its complications represent a global burden to human health. Among diabetic microvascular and macrovascular complications, diabetic cardiomyopathy (DCM) remains the primary and most prevalent condition leading to decreased cardiomyocyte function and risk of cardiac morbidities and mortality rate. Decreased cardiomyocyte function is mediated by the pathophysiological mechanisms broadly including glucotoxicity, endoplasmic reticulum stress, metabolic insulin signaling, mitochondrial dysfunction, oxidative stress, renin-angiotensin-aldosterone system activation, impaired calcium handling, apoptosis of cardiomyocytes, and cardiac lipotoxicity, which could be favorable targets for new therapeutic interventions. Currently, the treatment given in DCM is not enough in terms of cure; therefore, there is a need to introduce novel potential treatment options. Not any single therapeutic agent would treat DCM completely, so a variety of approaches are needed. The approaches can be a balanced outset of lifestyle modification, use of herbal and nutraceuticals, glucose control medication, antioxidants, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors to reduce the progression of DCM and effectively treat the patients. In the current review, emphasis has been made on the molecular mechanisms involved in the onset of DCM. We summarize the findings from preclinical and clinical studies including non-pharmacological strategies that might provide the directions for the development of targeted treatment approaches. Additionally, we discuss the novel and emerging therapeutic targets aimed at the management of DCM.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lung ultrasound in cardiac rehabilitation: expert consensus on protocols, clinical use, and integration into patient management from the working group on cardiac rehabilitation and cardiovascular prevention of the Italian society of cardiology. 心脏康复中的肺超声：意大利心脏病学会心脏康复和心血管预防工作组关于方案、临床使用和纳入患者管理的专家共识。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-22 DOI: 10.1007/s10741-025-10560-9

Costantino Mancusi, Francesco Giallauria, Mara Piccoli, Valeria Visco, Arturo Cesaro, Gerardina Fratianni, Elio Venturini, Nidal Turkmani, Antonello D'Andrea, Mario Pacileo, Raffaele Carluccio, Alessandro Maloberti, Nicola De Luca, Stefania Paolillo, Savina Nodari, Mauro Maniscalco, Pasquale Ambrosino, Alberto Palazzuoli, Paolo Calabrò, Michele Ciccarelli

{"title":"Lung ultrasound in cardiac rehabilitation: expert consensus on protocols, clinical use, and integration into patient management from the working group on cardiac rehabilitation and cardiovascular prevention of the Italian society of cardiology.","authors":"Costantino Mancusi, Francesco Giallauria, Mara Piccoli, Valeria Visco, Arturo Cesaro, Gerardina Fratianni, Elio Venturini, Nidal Turkmani, Antonello D'Andrea, Mario Pacileo, Raffaele Carluccio, Alessandro Maloberti, Nicola De Luca, Stefania Paolillo, Savina Nodari, Mauro Maniscalco, Pasquale Ambrosino, Alberto Palazzuoli, Paolo Calabrò, Michele Ciccarelli","doi":"10.1007/s10741-025-10560-9","DOIUrl":"https://doi.org/10.1007/s10741-025-10560-9","url":null,"abstract":"Lung ultrasonography (LUS) is a reliable and reproducible tool across various clinical settings. Its high diagnostic accuracy, portability, and real-time imaging capabilities make it especially suitable for use in Emergency Departments, Intensive Care Units, and outpatient clinics. LUS has proven particularly effective in evaluating lung congestion. LUS also provides superior diagnostic accuracy for detecting pleural effusion and lung consolidations, offering real-time imaging with high spatial resolution and enabling precise monitoring throughout hospitalization. In the Cardiac Rehabilitation Unit, the routine use of LUS represents a reliable imaging modality for assessing patients with complex clinical conditions. In fact, early identification of lung congestion, pleural effusion, or lung consolidation in patients recovering from acute coronary syndrome, acute heart failure, or cardiac surgery is crucial for optimizing clinical management. Moreover, continuous monitoring of lung congestion can aid in the appropriate adjustment of diuretic therapy and exercise intensity. This review aims to present the latest evidence and recommendations for the use of LUS in the cardiac rehabilitation setting.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac rehabilitation in patients with heart failure: clinical recommendation based on a review of the evidence. 心力衰竭患者的心脏康复：基于证据回顾的临床推荐。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-17 DOI: 10.1007/s10741-025-10561-8

Miguel Morita Fernandes-Silva, Fabrícia Daniela Martins Almeida, Veridiana Moraes D Avila, Mauricio Palu Gellatti, Guilherme Veiga Guimarães

引用次数: 0

Evaluation of pulmonary hypertension in heart failure with preserved ejection fraction. 保留射血分数心力衰竭患者肺动脉高压的评价。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-09 DOI: 10.1007/s10741-025-10553-8

Jenny Jia Ling Cao, Yogesh N V Reddy

引用次数: 0

Polypill in heart failure: a pathway to simplified treatment and improved adherence and outcomes. 多药片治疗心力衰竭：简化治疗和改善依从性和结果的途径。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-06 DOI: 10.1007/s10741-025-10559-2

Kalliopi Keramida, Gianluigi Savarese, Gerasimos Filippatos, Salim Yusuf

{"title":"Polypill in heart failure: a pathway to simplified treatment and improved adherence and outcomes.","authors":"Kalliopi Keramida, Gianluigi Savarese, Gerasimos Filippatos, Salim Yusuf","doi":"10.1007/s10741-025-10559-2","DOIUrl":"https://doi.org/10.1007/s10741-025-10559-2","url":null,"abstract":"Heart failure (HF) remains a global health challenge that imposes significant clinical and economic burden. Treatment adherence to guideline-directed medical therapy (GDMT) remains a major challenge in the management of HF, despite the availability of guideline-directed medical therapy (GDMT). Polypharmacy and regimen complexity contribute to poor adherence, particularly among older adults and in resource-limited settings. The polypill strategy, involving fixed-dose combinations of essential HF medications, has emerged as a potential solution to simplify treatment regimens, enhance adherence, and improve clinical outcomes. This review explores the potential of polypill therapy as a pragmatic strategy to simplify HF treatment and improve adherence. Drawing on its successful application in other cardiovascular diseases, we propose two implementation approaches for HF: early low-dose initiation for newly diagnosed patients or switching to a pre-specified dose polypill for stable, optimized patients. This review discusses formulations tailored to different HF phenotypes and highlights ongoing clinical trials assessing the efficacy and safety of the polypill in the HF setting. While the polypill approach offers promising benefits, i.e., improved adherence, affordability, and streamlined care, critical considerations regarding the selection of optimal drug components, identification and elimination of potential drug-drug interactions, the definition of appropriate flexible dose combinations, and patient-specific factors are crucial. Future research, particularly real-world clinical trials, is essential to comprehensively evaluate the efficacy, safety, and feasibility of polypill therapy in diverse HF patient populations, ensuring its responsible integration into clinical practice across diverse healthcare settings to mitigate the persistent burden of HF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypoalbuminemia in heart failure: pathophysiology, clinical implications, and management strategies. 心力衰竭中的低白蛋白血症：病理生理学、临床意义和管理策略。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-06 DOI: 10.1007/s10741-025-10558-3

Mohamad Ghazal, Wissam I Khalife

{"title":"Hypoalbuminemia in heart failure: pathophysiology, clinical implications, and management strategies.","authors":"Mohamad Ghazal, Wissam I Khalife","doi":"10.1007/s10741-025-10558-3","DOIUrl":"https://doi.org/10.1007/s10741-025-10558-3","url":null,"abstract":"Hypoalbuminemia is commonly seen in patients with heart failure and is associated with worse outcomes. Multiple pathophysiologic mechanisms can contribute to low albumin levels in heart failure patients, such as malnutrition, hepatic congestion, inflammation, and protein-losing enteropathy. Hypoalbuminemia can exacerbate heart failure symptoms and contributes to pulmonary edema by reducing plasma oncotic pressure, thereby favoring fluid movement into the interstitial and alveolar spaces. In this sense, albumin supplementation has been used in clinical practice to stimulate diuresis. However, evidence regarding its efficacy remains controversial. Routine albumin use does not appear to improve outcomes and should not be adopted broadly. Instead, it may be considered selectively in those with refractory edema or ascites despite maximal diuretic therapy and in whom hypoalbuminemia is profound. While proper oral nutrition has clearly shown better outcomes in malnourished heart failure patients, no clear guidelines about the use of intravenous albumin therapy are currently available to guide this practice. This article aims to review the pathophysiology of hypoalbuminemia in heart failure and the current available evidence on the therapeutic role of albumin infusion.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0